DUBLIN--(BUSINESS WIRE)--Sep 12, 2018--The "Contrave 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering.

The 5 Key Questions Addressed by this Report:

How many physicians were reached by Contrave through reportable promotional activity in 2017 and how does this compare to its peer set in the Obesity market? What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity? How does Orexigen and Takeda's depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, Obstetrics/Gynecology, and Endocrinology) and how does this compare to its peers and the overall set of rep-accessible physicians? How often are physicians receiving paid meals for Contrave throughout the year (e.g., monthly, quarterly, annually)? Who were the most frequent meal recipients and top paid speakers for Contrave in 2017?

For more information about this report visit https://www.researchandmarkets.com/research/9fsl7q/contrave_2017_u_s?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180912005974/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Anti-Obesity Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/12/2018 02:50 PM/DISC: 09/12/2018 02:50 PM

http://www.businesswire.com/news/home/20180912005974/en